Current challenges in clinical management of endometrial cancer

Advanced Drug Delivery Reviews

Volumn 61, Issue 10, 2009, Pages 883-889

  Montejo, Michael ^a   Werner, Theresa L ^a   Gaffney, David ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical management; Endometrial cancer; Mortality

Indexed keywords

BIOLOGIC BEHAVIOR; CLINICAL MANAGEMENT; DIAGNOSTIC IMAGING; ENDOMETRIAL CANCER; MANAGEMENT CHALLENGES; MORTALITY; NOVEL STRATEGIES; RADIATION DELIVERY; SYSTEMIC THERAPY;

MANAGEMENT;

DRUG DELIVERY;

AROMATASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOIC ACID RECEPTOR; STEROID HORMONE; TAMOXIFEN; THALIDOMIDE; TRASTUZUMAB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER STAGING; CARCINOGENESIS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOMETRIUM CANCER; HUMAN; HYSTERECTOMY; MOLECULAR BIOLOGY; MORBIDITY; NONHUMAN; PATIENT CARE PLANNING; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MASS SCREENING;

EID: 67649197359     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.04.014     Document Type: Review

References (104)

1. Jemal A., et al. Cancer statistics. CA Cancer J. Clin. 53 1 (2003) 5-26
2. Smith R.A., Cokkinides V., and Eyre H.J. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J. Clin. 57 2 (2007) 90-104
3. Fiegl H., et al. Methylated DNA collected by tampons-a new tool to detect endometrial cancer. Cancer Epidemiol. Biomark. Prev. 13 5 (2004) 882-888
4. Maida Y., et al. Is the telomerase assay useful for screening of endometrial lesions?. Int. J. Cancer 100 6 (2002) 714-718
5. Sommers S.C., and Meissner W.A. Endocrine abnormalities accompanying human endometrial cancer. Cancer 10 3 (1957) 516-521
6. Fisher B., et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 7 (1994) 527-537
7. Brinton L.A., and Hoover R.N. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet. Gynecol. 81 2 (1993) 265-271
8. Fung M.F., et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol. Oncol. 91 1 (2003) 154-159
9. Parsons R., et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75 6 (1993) 1227-1236
10. Lynch H.T., et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104 5 (1993) 1535-1549
11. Lecuru F., et al. Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study. Fam. Can. 6 3 (2007) 295-299
12. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15 1 (1983) 10-17
13. Deligdisch L., and Holinka C.F. Endometrial carcinoma: two diseases?. Cancer Detect. Prev. 10 3-4 (1987) 237-246
14. Lax S.F., et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 4 (2000) 814-824
15. Tashiro H., et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 150 1 (1997) 177-185
16. Moll U.M., et al. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum. Pathol. 27 12 (1996) 1295-1300
17. Sung C.J., et al. p53 as a significant prognostic marker in endometrial carcinoma. Int. J. Gynecol. Cancer 10 2 (2000) 119-127
18. Geisler J.P., et al. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol. Oncol. 74 3 (1999) 468-471
19. Tashiro H., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57 18 (1997) 3935-3940
20. Risinger J.I., et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 57 21 (1997) 4736-4738
21. Risinger J.I., et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res. 4 12 (1998) 3005-3010
22. Susini T., et al. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors. Cancer 109 5 (2007) 882-890
23. Paik S., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351 27 (2004) 2817-2826
24. Asad J., et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?. Am. J. Surg. 196 4 (2008) 527-529
25. Torres-Roca J.F., et al. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 65 16 (2005) 7169-7176
26. Lee C.M., et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 295 4 (2006) 389-397
27. Lee C.M., et al. Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: a surveillance, epidemiology, and end results population study. Cancer 110 9 (2007) 2092-2100
28. Fuller J., et al. Lymph edema of the lower extremities after lymphadenectomy and radiotherapy for cervical cancer. Strahlenther. Onkol. 184 4 (2008) 206-211
29. Tanaka T., et al. Radiotherapy negates the effect of retroperitoneal nonclosure for prevention of lymphedema of the legs following pelvic lymphadenectomy for gynecological malignancies: an analysis from a questionnaire survey. Int. J. Gynecol. Cancer 17 2 (2007) 460-464
30. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer. Available at http://www.nccn.org. Accessed August 20, 2008.
31. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Melanoma. Available at http://www.nccn.org. Accessed August 20, 2008.
32. Delpech Y., et al. The sentinel node concept in endometrial cancer: histopathologic validation by serial section and immunohistochemistry. Ann. Oncol. 18 11 (2007) 1799-1803
33. Selman T.J., et al. A systematic review of tests for lymph node status in primary endometrial cancer. BMC Womens Health 8 (2008) 8
34. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Endometrial Cancer. Available at http://www.nccn.org. Accessed January 7, 2009.
35. Creasman W.T., et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60 8 Suppl (1987) 2035-2041
36. Surwit E.A., et al. Stage II carcinoma of the endometrium. Int. J. Radiat. Oncol. Biol. Phys. 5 3 (1979) 323-326
37. Rockall A.G., et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J. Clin. Oncol. 23 12 (2005) 2813-2821
38. Harisinghani M.G., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348 25 (2003) 2491-2499
39. Kitajima K., et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am. J. Roentgenol. 190 6 (2008) 1652-1658
40. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Endometrial Cancer. Available at http://www.nccn.org. Accessed August 20, 2008.
41. Creutzberg C.L., et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J. Clin. Oncol. 22 7 (2004) 1234-1241
42. Keys H.M., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92 3 (2004) 744-751
43. Creutzberg C.L., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 9213 (2000) 1404-1411
44. Aalders J., et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet. Gynecol. 56 4 (1980) 419-427
45. Emami B., et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 21 1 (1991) 109-122
46. Roeske J.C., et al. Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix: a dosimetric analysis. Int. J. Radiat. Oncol. Biol. Phys. 37 2 (1997) 351-358
47. Perez C.A., et al. Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. Int. J. Radiat. Oncol. Biol. Phys. 44 4 (1999) 855-866
48. Portelance L., et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 51 1 (2001) 261-266
49. Roeske J.C., et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 48 5 (2000) 1613-1621
50. Mundt A.J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 52 5 (2002) 1330-1337
51. Mundt A.J., Mell L.K., and Roeske J.C. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 56 5 (2003) 1354-1360
52. Brixey C.J., et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 54 5 (2002) 1388-1396
53. Mohan D.S., et al. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol. Oncol. 70 2 (1998) 165-171
54. Podratz K.C., Mariani A., and Webb M.J. Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol. Oncol. 70 2 (1998) 163-164
55. Decruze S.B., and Green J.A. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int. J. Gynecol. Cancer 17 5 (2007) 964-978
56. Thigpen J.T., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 17 6 (1999) 1736-1744
57. Fiorica J.V., et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92 1 (2004) 10-14
58. Whitney C.W., et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92 1 (2004) 4-9
59. Thigpen J.T., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 22 19 (2004) 3902-3908
60. Fleming G.F., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann. Oncol. 15 8 (2004) 1173-1178
61. Fleming G.F., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22 11 (2004) 2159-2166
62. Hoskins P.J., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19 20 (2001) 4048-4053
63. Price F.V., et al. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin. Oncol. 24 5 Suppl 15 (1997) S15-78-S15-82
64. Sovak M.A., et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol. Oncol. 103 2 (2006) 451-457
65. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 5 (2005) 1011-1027
66. Yokoyama Y., et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin. Cancer Res. 9 4 (2003) 1361-1369
67. Giatromanolaki A., et al. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 92 10 (2001) 2569-2577
68. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 6 (2003) 669-676
69. Bevacizumab (Avastin) Full Prescribing Information Sheet, Genentech, revised March 2008.
70. Burger R.A. Experience with bevacizumab in the management of epithelial ovarian cancer. J. Clin. Oncol. 25 20 (2007) 2902-2908
71. Yokoyama Y., et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol. Oncol. 77 3 (2000) 413-418
72. Fine B.A., et al. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol. Oncol. 76 1 (2000) 33-39
73. Kadar N., Malfetano J.H., and Homesley H.D. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol. Oncol. 50 3 (1993) 281-286
74. Ehrlich C.E., et al. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am. J. Obstet. Gynecol. 158 4 (1988) 796-807
75. Fukuda K., et al. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol. Oncol. 69 3 (1998) 220-225
76. Mortel R., Zaino R., and Satyaswaroop P.G. Heterogeneity and progesterone-receptor distribution in endometrial adenocarcinoma. Cancer 53 1 (1984) 113-116
77. Ma W., et al. Adult tissue angiogenesis: evidence for negative regulation by estrogen in the uterus. Mol. Endocrinol. 15 11 (2001) 1983-1992
78. Walter L.M., Rogers P.A., and Girling J.E. The role of progesterone in endometrial angiogenesis in pregnant and ovariectomised mice. Reproduction 129 6 (2005) 765-777
79. Hyder S.M., et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res. 60 12 (2000) 3183-3190
80. Buteau-Lozano H., et al. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res. 62 17 (2002) 4977-4984
81. Smith I., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 9555 (2007) 29-36
82. Slamon D.J., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
83. Morrison C., et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J. Clin. Oncol. 24 15 (2006) 2376-2385
84. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 11 (2001) 783-792
85. Piccart-Gebhart M.J., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 16 (2005) 1659-1672
86. Trastuzumab (Herceptin) Full Prescribing Information Sheet, Genentech, revised May 2008.
87. Riben M.W., et al. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod. Pathol. 10 8 (1997) 823-831
88. Saffari B., et al. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res. 55 23 (1995) 5693-5698
89. Parazzini F., et al. Diabetes and endometrial cancer: an Italian case-control study. Int. J. Cancer 81 4 (1999) 539-542
90. Swanson C.A., et al. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution. Cancer Epidemiol. Biomark. Prev. 2 4 (1993) 321-327
91. Sturgeon S.R., et al. Past and present physical activity and endometrial cancer risk. Br. J. Cancer 68 3 (1993) 584-589
92. Shu X.O., et al. Physical activity and risk of endometrial cancer. Epidemiology 4 4 (1993) 342-349
93. Soler M., et al. Hypertension and hormone-related neoplasms in women. Hypertension 34 2 (1999) 320-325
94. Cust A.E., et al. Dietary carbohydrates, glycemic index, glycemic load, and endometrial cancer risk within the European Prospective Investigation into Cancer and Nutrition cohort. Am. J. Epidemiol. 166 8 (2007) 912-923
95. Gunter M.J., et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol. Biomark. Prev. 17 4 (2008) 921-929
96. Patel A.V., et al. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int. J. Cancer 123 8 (2008) 1877-1882
97. Lindemann K., et al. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br. J. Cancer 98 9 (2008) 1582-1585
98. Schmeler K.M., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N. Engl. J. Med. 354 3 (2006) 261-269
99. Pistorius S., et al. Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients. Gynecol. Oncol. 102 2 (2006) 189-194
100. Ota K., et al. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin. Cancer Res. 12 14 Pt 1 (2006) 4200-4208
101. Wu W., et al. Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. Int. J. Gynecol. Cancer 18 2 (2008) 329-338
102. Tanabe K., et al. Expression of retinoic acid receptors in human endometrial carcinoma. Cancer Sci. 99 2 (2008) 267-271
103. Nasir A., et al. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo 21 1 (2007) 35-43
104. Chen X.J., et al. Telomerase antisense inhibition for the proliferation of endometrial cancer in vitro and in vivo. Int. J. Gynecol. Cancer 16 6 (2006) 1987-1993